Literature DB >> 23897372

Cardiac amyloidosis masquerading as biventricular hypertrophy in a patient with multiple myeloma.

Haseeb Ilias Basha1, Ethiraj Raj, Ghassan Bachuwa.   

Abstract

Cardiac amyloidosis or amyloid cardiomyopathy is a rare disorder characterised by extracellular deposition of insoluble polymers composed of low-molecular-weight subunit proteins within the myocardium. This often results in an infiltrative cardiomyopathy with restrictive pathophysiology, leading to progressive heart failure. In this report, we present an interesting case of cardiac amyloidosis that eventually led to the diagnosis of underlying multiple myeloma in a patient with no previous cardiac history. Cardiac amyloidosis should be suspected in patients with unexplained congestive heart-failure symptoms accompanied by low-voltage complexes on ECG, preserved ejection fraction with asymmetric ventricular hypertrophy and abnormal myocardial texture, described as 'granular sparkling' on echocardiogram. Patients with cardiac amyloidosis should be closely monitored as mortality remains high, despite advances in treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23897372      PMCID: PMC3736195          DOI: 10.1136/bcr-2012-008113

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Authors:  D R Jacobson; R D Pastore; R Yaghoubian; I Kane; G Gallo; F S Buck; J N Buxbaum
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

2.  Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.

Authors:  P A Pellikka; D R Holmes; W D Edwards; R A Nishimura; A J Tajik; R A Kyle
Journal:  Arch Intern Med       Date:  1988-03

3.  Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis.

Authors:  S W Dubrey; K Cha; R W Simms; M Skinner; R H Falk
Journal:  Am J Cardiol       Date:  1996-02-01       Impact factor: 2.778

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Signal-averaged electrocardiography in patients with AL (primary) amyloidosis.

Authors:  S W Dubrey; S Bilazarian; M LaValley; J Reisinger; M Skinner; R H Falk
Journal:  Am Heart J       Date:  1997-12       Impact factor: 4.749

6.  Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Authors:  Giovanni Palladini; Vittorio Perfetti; Laura Obici; Riccardo Caccialanza; Alessandra Semino; Fausto Adami; Giobatta Cavallero; Roberto Rustichelli; Giovambattista Virga; Giampaolo Merlini
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

7.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

8.  Clinical significance of histopathologic patterns of cardiac amyloidosis.

Authors:  T J Smith; R A Kyle; J T Lie
Journal:  Mayo Clin Proc       Date:  1984-08       Impact factor: 7.616

9.  Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients.

Authors:  E Arbustini; G Merlini; A Gavazzi; M Grasso; M Diegoli; R Fasani; V Bellotti; G Marinone; P Morbini; B Dal Bello
Journal:  Am Heart J       Date:  1995-09       Impact factor: 4.749

10.  Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

Authors:  Vaishali Sanchorawala; Daniel G Wright; David C Seldin; Rodney H Falk; John L Berk; Laura M Dember; Kathleen T Finn; Martha Skinner
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.